3060 PEGASUS PARK DRIVE, DALLAS, TX
ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING
Investor Presentation
Shareholder votes
Earnings Release
Other Events
Announces Results and Provides Clinical Update
Announces Oversubscribed $53 Million Private Placement from Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Definitive Additional Information Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership